Bioventus Inc.
BVS- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001665988
No open-market purchases or sales by Bioventus Inc. insiders were filed in the last 90 days; 156 institutions reported holding it in 13F filings for Q2 2026, worth $509.4M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Bioventus Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +21 vs. Q1 2024
- Shares held
- 38.7M
- +4.44M (+13.0%) vs. Q1 2024
- Total value
- $222.2M
- +$44.3M (+24.9%) vs. Q1 2024
- New holders
- 40
- 30 more added
- Sold out
- 19
- 20 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 156 | $509.4M |
| Q1 2026 | 157 | $466.4M |
| Q4 2025 | 148 | $373.3M |
| Q3 2025 | 135 | $328.9M |
| Q2 2025 | 134 | $320.3M |
| Q1 2025 | 144 | $427.0M |
| Q4 2024 | 151 | $477.8M |
| Q3 2024 | 138 | $537.1M |
| Q2 2024 | 103 | $222.2M |
| Q1 2024 | 84 | $178.0M |
| Q4 2023 | 80 | $175.4M |
| Q3 2023 | 67 | $108.9M |
| Q2 2023 | 66 | $92.6M |
| Q1 2023 | 71 | $33.4M |
| Q4 2022 | 85 | $81.9M |
| Q3 2022 | 94 | $245.9M |
| Q2 2022 | 98 | $232.0M |
| Q1 2022 | 105 | $447.0M |
| Q4 2021 | 98 | $451.6M |
| Q3 2021 | 69 | $351.8M |
| Q2 2021 | 53 | $364.5M |
| Q1 2021 | 45 | $334.2M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Bioventus Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 5,338,314 | $30.7M | 3.08% | −467,698−8.1% | Reduced |
| Juniper Investment Company, LLC | 6,833,857 | $39.3M | 18.84% | 00.0% | Unchanged |
| Essex Woodlands Management, Inc. | 13,021,324 | $74.9M | 24.41% | 00.0% | Unchanged |
| Alberta Investment Management Corp | 0 | $0 | 0.00% | −152,227−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −118,291−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −77,808−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −53,696−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −50,027−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −26,664−100.0% | Sold out |
| GSG Advisors LLC | 0 | $0 | 0.00% | −26,511−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −21,700−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −19,498−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −18,613−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −16,227−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −12,933−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −10,938−100.0% | Sold out |
| Gladius Capital Management LP | 0 | $0 | 0.00% | −7,773−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −5,051−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −4,450−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −86−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −1,809−100.0% | Sold out |
| Cutler Group LP | – | – | – | – | Not filed |
| Shell Asset Management Co | – | – | – | – | Not filed |